Cargando…
Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal...
Autores principales: | Metadilogkul, Orapun, Jirathitikal, Vichai, Bourinbaiar, Aldar S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577775/ https://www.ncbi.nlm.nih.gov/pubmed/18989372 http://dx.doi.org/10.1155/2009/934579 |
Ejemplares similares
-
Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia
por: Bourinbaiar, Aldar, et al.
Publicado: (2010) -
Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study
por: Bourinbaiar, Aldar S, et al.
Publicado: (2010) -
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
por: Butov, Dmitry A, et al.
Publicado: (2011) -
Immunotherapy of liver cancer with hepcortespenlisimut-L: open-label Phase II clinical study in patients with advanced HCC
por: Tarakanovskaya, Marina G, et al.
Publicado: (2015) -
Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L
por: Tarakanovskaya, Marina G, et al.
Publicado: (2017)